TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Go back to TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE| Amgen Inc (NASDAQ: AMGN) | Delayed: 395.83 -41.4 (9.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $437.23 | 52 Week High | $176.85 | |||
| Open | $408.90 | 52 Week Low | $133.64 | |||
| Day High | $410.03 | P/E | 59.61 | |||
| Day Low | $392.00 | EPS | $6.64 | |||
| Volume | 3,120,472 | |||||

